Global Information
회사소개 | 문의 | 위시리스트

중동의 암진단 시장 : 매출 예측, 시장 전략, 공급업체의 시장 점유율 - 새로운 종양마커, 기술, 시장 기회

Middle East Tumor Marker Testing Market, 2019-2023: An 11-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Tests, Technologies and Opportunities

리서치사 Venture Planning Group
발행일 상품 코드 445422
페이지 정보 영문 530 Pages
가격
US $ 7,500 ₩ 9,192,000 DataPack (Local License)
US $ 9,850 ₩ 12,073,000 PDF by E-mail (Local license)
US $ 14,750 ₩ 18,079,000 PDF by E-mail (Global license)


중동의 암진단 시장 : 매출 예측, 시장 전략, 공급업체의 시장 점유율 - 새로운 종양마커, 기술, 시장 기회 Middle East Tumor Marker Testing Market, 2019-2023: An 11-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Tests, Technologies and Opportunities
발행일 : 페이지 정보 : 영문 530 Pages

중동 국가(총 11개국)의 암진단 검사(종양마커 검사 등) 시장을 분석했으며, 진단 방법 개요, 현재의 기술 수준, 현재의 주요 진단약 및 검사 방법, 국가별·진단 방법별 동향 전망(향후 5년간), 주요 공급업체의 프로파일·제품 포트폴리오·사업 전략, 향후 시장 기회 등의 정보를 정리하여 전해드립니다.

1. 목차 및 도표

2. 국가별 시장 동향

  • 바레인
  • 이란
  • 이라크
  • 이스라엘
  • 요르단
  • 쿠웨이트
  • 레바논
  • 오만
  • 카타르
  • 사우디아라비아
  • 아랍에미리트(UAE)

3. 종양마커 분류

4. 각종 암/종양마커용 진단약 개발 및 출시 상황

  • ACTH 검사
  • AFP 검사
  • β-2 마이크로글로불린 검사
  • CA 15-3/27.29 검사
  • CA 19-9 검사
  • CA-125 검사
  • 칼시토닌 검사
  • CEA 검사
  • 에스트로겐 수용체 검사
  • 프로게스테론 수용체 검사
  • 페리틴 검사
  • 가스트린 검사
  • HCG 검사
  • 인슐린 검사
  • NSE 검사
  • 잠혈 검사
  • PAP Smear/HPV 검사
  • PAP 검사
  • PSA 검사
  • 림프구 세분류 검사(Lymphocyte Subclassification Tests)

5. 암진단의 잠재적 이용 가능성

  • 생화학표지자(Biochemical Marker)
  • 발암 유전자(Oncogenes)
  • 성장인자(Growth Factors)
  • 콜로니자극인자(Colony Stimulating Factors)
  • 림포카인(Lymphokines)
  • 면역조직화학 염색(Immunohistochemical Stain)
LSH 17.03.06

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

This new 11-country report from LeadingMarketResearch.com is available by country, market segment, section, or individual test.

This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.

The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Country Analyses

Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab Emirates

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Tests

- Oncogenes - Biochemical Markers - Growth Factors - Colony Stimulating Factors - Hormones - Immunohistochemical Stains - Lymphokines

- ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Instrumentation Review

- Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

- Assessment of latest technologies and their potential applications for cancer diagnostic testing.

- Review of competing/complementing technologies.

- Companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

- Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

- The companies analyzed in the report include:

- Abbott Agilent Technologies Applied Gene Technologies Arca Biopharma Beckman Coulter/Danaher Becton Dickinson bioMerieux Bio-Rad CellSearch Cepheid Clinical Genomics Decode Genetics DiaSorin Diazyme Eiken Chemical Elitech Group Enzo Biochem Epigenomics Exact Sciences Fujirebio Guided Therapeutics Hologic Janssen Diagnostics Leica Biosystems Kyowa Medex Myriad Genetics OncoLab Ortho-Clinical Diagnostics Panacea Pharmaceuticals PerkinElmer Polymedco Qiagen Quest Diagnostics Roche Scienion Sequenom Siemens Healthineers Takara Bio Theradiag Thermo Fisher Tosoh Vermillion Wako Pure Chemicals

Contains 530 pages and 50 tables

Table of Contents

List of Tables

  • Bahrain Cancer Diagnostic Volume Forecasts by Test
  • Bahrain Cancer Diagnostics Sales Forecasts by Test
  • Iran Cancer Diagnostic Volume Forecasts by Test
  • Iran Cancer Diagnostics Sales Forecasts by Test
  • Iraq Cancer Diagnostic Volume Forecasts by Test
  • Iraq Cancer Diagnostics Sales Forecasts by Test
  • Israel Cancer Diagnostic Volume Forecasts by Test
  • Israel Cancer Diagnostics Sales Forecasts by Test
  • Jordan Cancer Diagnostic Volume Forecasts by Test
  • Jordan Cancer Diagnostics Sales Forecasts by Test
  • Kuwait Cancer Diagnostic Volume Forecasts by Test
  • Kuwait Cancer Diagnostics Sales Forecasts by Test
  • Lebanon Cancer Diagnostic Volume Forecasts by Test
  • Lebanon Cancer Diagnostics Sales Forecasts by Test
  • Oman Cancer Diagnostic Volume Forecasts by Test
  • Oman Cancer Diagnostics Sales Forecasts by Test
  • Qatar Cancer Diagnostic Volume Forecasts by Test
  • Qatar Cancer Diagnostics Sales Forecasts by Test
  • Saudi Arabia Cancer Diagnostic Volume Forecasts by Test
  • Saudi Arabia Cancer Diagnostics Sales Forecasts by Test
  • United Arab Emirates Cancer Diagnostic Volume Forecasts by Test
  • United Arab Emirates Cancer Diagnostics Sales Forecasts by Test
  • Tumor Marker Classification
  • Major Companies Developing or Marketing ACTH Tests
  • Major Companies Developing or Marketing AFP Tests
  • Major Companies Developing or Marketing Beta-2 Microglobulin Tests
  • Major Companies Developing or Marketing CA 15-3/27.29 Tests
  • Major Companies Developing or Marketing CA 19-9 Tests
  • Major Companies Developing or Marketing CA 125 Tests
  • Major Companies Developing or Marketing Calcitonin Tests
  • Major Companies Developing or Marketing CEA Tests
  • Major Companies Developing or Marketing Estrogen Receptor Tests
  • Major Companies Developing or Marketing Progesterone Receptor Tests
  • Major Companies Developing or Marketing Ferritin Tests
  • Major Companies Developing or Marketing Gastrin Tests
  • Major Companies Developing or Marketing HCG Tests
  • Major Companies Developing or Marketing Insulin Tests
  • Major Companies Developing or Marketing NSE Tests
  • Major Companies Developing or Marketing Occult Blood Tests
  • Major Companies Developing or Marketing PAP Smear/HPV Tests
  • Major Companies Developing or Marketing PAP Tests
  • Major Companies Developing or Marketing PSA Tests
  • Major Companies Developing or Marketing Lymphocyte Subclassification Tests
  • Biochemical Markers Potential Applications In Cancer Diagnosis
  • Oncogenes Potential Applications In Cancer Diagnosis
  • Major Companies Developing or Marketing Oncogene Tests
  • Growth Factors Potential Applications In Cancer Diagnosis
  • Colony Stimulating Factors Potential Applications in Cancer Diagnosis
  • Lymphokines Potential Applications in Cancer Diagnosis
  • Immunohistochemical Stains Potential Applications in Cancer Diagnosis
Back to Top
전화 문의
F A Q